Class information for:
Level 1: AVIBACTAM//CEFTOLOZANE TAZOBACTAM//CEFTAZIDIME AVIBACTAM

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
22341 385 39.7 77%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
7 4 INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY 1353914
73 3       MICROBIOLOGY//INFECTIOUS DISEASES//STAPHYLOCOCCUS AUREUS 82747
233 2             ACINETOBACTER BAUMANNII//EXTENDED SPECTRUM BETA LACTAMASE//ESBL 20247
22341 1                   AVIBACTAM//CEFTOLOZANE TAZOBACTAM//CEFTAZIDIME AVIBACTAM 385

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 AVIBACTAM authKW 1399054 5% 84% 21
2 CEFTOLOZANE TAZOBACTAM authKW 1284848 5% 90% 18
3 CEFTAZIDIME AVIBACTAM authKW 1273394 4% 94% 17
4 CEFTOLOZANE authKW 642424 2% 90% 9
5 PLAZOMICIN authKW 494168 2% 69% 9
6 ACHN 490 authKW 396559 1% 100% 5
7 FR264205 authKW 317247 1% 100% 4
8 CXA 201 authKW 237936 1% 100% 3
9 MK 7655 authKW 237936 1% 100% 3
10 LACTAMASE INHIBITORS authKW 211496 1% 67% 4

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Microbiology 9072 63% 0% 244
2 Pharmacology & Pharmacy 6370 74% 0% 283
3 Infectious Diseases 3358 28% 0% 108
4 Chemistry, Medicinal 43 4% 0% 15
5 Immunology 10 4% 0% 17
6 Chemistry, Organic 2 3% 0% 11
7 Toxicology 1 1% 0% 5
8 Medicine, General & Internal 0 2% 0% 9
9 Biochemical Research Methods 0 1% 0% 5
10 Critical Care Medicine 0 1% 0% 2

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ANTIINFECT DEV 133460 5% 8% 21
2 INFECT INNOVAT MED 110334 2% 17% 8
3 ALUMNI ASSOC NEPAL 79312 0% 100% 1
4 ANT BACTERIAL DISCOVERY PERFORMANCE UNIT 79312 0% 100% 1
5 BIOFUNCT NANOMAT GRP 79312 0% 100% 1
6 CLIN PHARMACOL TRIAL UNIT 79312 0% 100% 1
7 CRIT CARE ALLERGY CLIN IMMUNOL 79312 0% 100% 1
8 DEP MED PREVENT SALUD PUBL MICROBIOL 79312 0% 100% 1
9 DIAGNOST BIOMEDMICROBIOL SERV 79312 0% 100% 1
10 DISCOVERY SCI INNOVAT MED UNIT 79312 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 57054 34% 1% 130
2 JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 10675 11% 0% 41
3 INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 10024 6% 1% 22
4 JOURNAL DES ANTI-INFECTIEUX 4283 1% 3% 2
5 EXPERT REVIEW OF ANTI-INFECTIVE THERAPY 3940 2% 1% 7
6 DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE 2131 3% 0% 12
7 REVISTA ESPANOLA DE QUIMIOTERAPIA 1810 1% 1% 3
8 FUTURE MICROBIOLOGY 1266 1% 0% 4
9 EXPERT OPINION ON INVESTIGATIONAL DRUGS 915 1% 0% 5
10 IDRUGS 847 1% 1% 2

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 AVIBACTAM 1399054 5% 84% 21 Search AVIBACTAM Search AVIBACTAM
2 CEFTOLOZANE TAZOBACTAM 1284848 5% 90% 18 Search CEFTOLOZANE+TAZOBACTAM Search CEFTOLOZANE+TAZOBACTAM
3 CEFTAZIDIME AVIBACTAM 1273394 4% 94% 17 Search CEFTAZIDIME+AVIBACTAM Search CEFTAZIDIME+AVIBACTAM
4 CEFTOLOZANE 642424 2% 90% 9 Search CEFTOLOZANE Search CEFTOLOZANE
5 PLAZOMICIN 494168 2% 69% 9 Search PLAZOMICIN Search PLAZOMICIN
6 ACHN 490 396559 1% 100% 5 Search ACHN+490 Search ACHN+490
7 FR264205 317247 1% 100% 4 Search FR264205 Search FR264205
8 CXA 201 237936 1% 100% 3 Search CXA+201 Search CXA+201
9 MK 7655 237936 1% 100% 3 Search MK+7655 Search MK+7655
10 LACTAMASE INHIBITORS 211496 1% 67% 4 Search LACTAMASE+INHIBITORS Search LACTAMASE+INHIBITORS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 BUSH, K , (2015) A RESURGENCE OF BETA-LACTAMASE INHIBITOR COMBINATIONS EFFECTIVE AGAINST MULTIDRUG-RESISTANT GRAM-NEGATIVE PATHOGENS.INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. VOL. 46. ISSUE 5. P. 483 -493 71 60% 18
2 GARDINER, BJ , GOLAN, Y , (2016) CEFTAZIDIME-AVIBACTAM (CTZ-AVI) AS A TREATMENT FOR HOSPITALIZED ADULT PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS.EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. VOL. 14. ISSUE 5. P. 451 -463 65 78% 0
3 GOODLET, KJ , NICOLAU, DP , NAILOR, MD , (2016) CEFTOLOZANE/TAZOBACTAM AND CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS.THERAPEUTICS AND CLINICAL RISK MANAGEMENT. VOL. 12. ISSUE . P. 1811 -1826 63 79% 0
4 VAN DUIN, D , BONOMO, RA , (2016) CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM: SECOND-GENERATION BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS.CLINICAL INFECTIOUS DISEASES. VOL. 63. ISSUE 2. P. 234 -241 38 76% 7
5 SCOTT, LJ , (2016) CEFTOLOZANE/TAZOBACTAM: A REVIEW IN COMPLICATED INTRA-ABDOMINAL AND URINARY TRACT INFECTIONS.DRUGS. VOL. 76. ISSUE 2. P. 231 -242 29 88% 5
6 MAWAL, Y , CRITCHLEY, IA , RICCOBENE, TA , TALLEY, AK , (2015) CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND COMPLICATED INTRA-ABDOMINAL INFECTIONS.EXPERT REVIEW OF CLINICAL PHARMACOLOGY. VOL. 8. ISSUE 6. P. 691 -707 37 67% 5
7 ZHANEL, GG , CHUNG, P , ADAM, H , ZELENITSKY, S , DENISUIK, A , SCHWEIZER, F , LAGACE-WIENS, PRS , RUBINSTEIN, E , GIN, AS , WALKTY, A , ET AL (2014) CEFTOLOZANE/TAZOBACTAM: A NOVEL CEPHALOSPORIN/BETA-LACTAMASE INHIBITOR COMBINATION WITH ACTIVITY AGAINST MULTIDRUG-RESISTANT GRAM-NEGATIVE BACILLI.DRUGS. VOL. 74. ISSUE 1. P. 31-51 28 67% 51
8 PAPP-WALLACE, KM , BONOMO, RA , (2016) NEW BETA-LACTAMASE INHIBITORS IN THE CLINIC.INFECTIOUS DISEASE CLINICS OF NORTH AMERICA. VOL. 30. ISSUE 2. P. 441 -+ 36 57% 3
9 BOUCHER, HW , TALBOT, GH , BENJAMIN, DK , BRADLEY, J , GUIDOS, RJ , JONES, RN , MURRAY, BE , BONOMO, RA , GILBERT, D , (2013) 10 X '20 PROGRESS-DEVELOPMENT OF NEW DRUGS ACTIVE AGAINST GRAM-NEGATIVE BACILLI: AN UPDATE FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA.CLINICAL INFECTIOUS DISEASES. VOL. 56. ISSUE 12. P. 1685-1694 22 58% 237
10 ZASOWSKI, EJ , RYBAK, JM , RYBAK, MJ , (2015) THE -LACTAMS STRIKE BACK: CEFTAZIDIME-AVIBACTAM.PHARMACOTHERAPY. VOL. 35. ISSUE 8. P. 755 -770 28 67% 14

Classes with closest relation at Level 1


Rank Class id link
1 11854 TELAVANCIN//CEFTAROLINE//LIPOGLYCOPEPTIDE
2 25741 ANTIBACTERIAL DRUG DEVELOPMENT//INFECT GLOBAL MED DEV//ANTIBIOTIC INNOVATION
3 4087 BETA LACTAMASE//PENICILLIN BINDING PROTEIN//INGN PROT
4 1324 CARBAPENEMASE//METALLO BETA LACTAMASE//KPC
5 9318 OPRD//PSEUDOMONAS AERUGINOSA//MEXXY
6 8152 BURNS TRAUMA CRIT CARE//MEROPENEM//AUGMENTED RENAL CLEARANCE
7 15552 TIGECYCLINE//GLYCYLCYCLINE//GAR 936
8 18692 METALLO BETA LACTAMASE//INGN PROT//ZINC BETA LACTAMASE
9 99 EXTENDED SPECTRUM BETA LACTAMASE//ESBL//CTX M
10 23535 PEPTIDE DEFORMYLASE//PEPTIDE DEFORMYLASE INHIBITORS//DEFORMYLASE

Go to start page